SciClone Pharmaceuticals to Present at RBC Capital Markets' Global Healthcare Conference
(firmenpresse) - FOSTER CITY, CA -- (Marketwire) -- 02/22/12 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Gary Titus, Chief Financial Officer, will present a corporate overview and business update at the RBC Capital Markets' Global Healthcare Conference on February 29, 2012 at 12:00 noon ET at the New York Palace Hotel in New York City.
To access the live audio webcast of the presentation, please log on through a link located in the Investor Relations section of SciClone's website at , under the Calendar of Events tab. A replay of the webcast will be available one hour after the conclusion of the live event.
SciClone Pharmaceuticals is a revenue-generating, profitable, specialty pharmaceutical company with a substantial commercial business in China and a product portfolio of therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders. SciClone's ZADAXIN® (thymalfasin) is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), as a vaccine adjuvant, and certain cancers according to the local regulatory approvals. Besides ZADAXIN, SciClone markets nearly 20 mostly partnered products in China, including Depakine®, the most widely prescribed broad-spectrum anti-convulsant in China; Tritace®, an ACE inhibitor for the treatment of hypertension; Stilnox®, a fast-acting hypnotic for the short-term treatment of insomnia (marketed as Ambien® in the US); and Aggrastat®, a recently-launched interventional cardiology product. SciClone is also developing SCV-07 in a phase 2b trial for the delay to onset of oral mucositis in patients with head and neck cancer. SciClone is also pursuing the registration of several other therapeutic products in China. SciClone is headquartered in Foster City, California. For additional information, please visit .
Ambien, Depakine, Stilnox and Tritace are registered trademarks of Sanofi.
Aggrastat is a registered trademark of Merck & Co., Inc.
Gary Titus
Chief Financial Officer
650.358.3456
Jane Green
Investors/Media
650.358.1447
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 22.02.2012 - 06:00 Uhr
Sprache: Deutsch
News-ID 1085404
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
FOSTER CITY, CA
Phone:
Kategorie:
Drugs
Anmerkungen:
Diese Pressemitteilung wurde bisher 110 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"SciClone Pharmaceuticals to Present at RBC Capital Markets' Global Healthcare Conference
"
steht unter der journalistisch-redaktionellen Verantwortung von
SciClone Pharmaceuticals, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
